SCHEMBL21995304

SCHEMBL21995304

O=C(O)N1Cc2[nH]nc(I)c2C1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 10/20 0.39
CDK2 P24941 10/20 0.39
CCNA1 P78396 10/20 0.39
AURKA O14965 7/20 0.39
BRD4 O60885 2/20 0.33
CREBBP Q92793 2/20 0.33
EP300 Q09472 1/20 0.33
HCAR2 Q8TDS4 4/20 0.33
KMT2A Q03164 1/20 0.33
TSHR P16473 1/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818349 0.85 CREBBP (0.44) BRD4CREBBPEP300HCAR2KMT2A
SCHEMBL17317850 0.85 P2RX7 (0.39) CCNA2CDK2CCNA1AURKABRD4
SCHEMBL1704668 0.79 CCNA2 (0.42) CCNA2CDK2CCNA1AURKABRD4
SCHEMBL2387629 0.79 CCNA2 (0.39) CCNA2CDK2CCNA1AURKABRD4
SCHEMBL5720844 0.77 NR1H2 (0.40) CCNA2CDK2CCNA1AURKA
SCHEMBL5720833 0.77 CCNA2 (0.49) CCNA2CDK2CCNA1AURKA
SCHEMBL18880484 0.73 MAPK1 (0.47) CCNA2CDK2CCNA1AURKABRD4
SCHEMBL28378565 0.73
SCHEMBL21995408 0.73 LMNA (0.42) CCNA2CDK2CCNA1AURKAKMT2A
SCHEMBL28739856 0.72 BRD4 (0.61) CCNA2CDK2CCNA1AURKABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473502-B 4, 6-dihydropyrrolo [3,4-C ] pyrazole-5 (1H) -carbonitrile derivatives for the treatment of cancer 特殊治疗有限公司 2022-04-26 CN disclosed
EP-3887371-A1 ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2021-10-06 EP disclosed
WO-2020109191-A1 ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2020-06-04 WO disclosed